Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Pharmaceuticals  // Browsing posts in Pharmaceuticals

Camurus and Indivior Set to Significantly Sway the Opioid Abuse Treatment Market (INDV)

Research Question: How will the new long-acting buprenorphine options and changing government rules affect the opioid abuse treatment market? Companies: ALKS, DEPO, LON:INDV, STO:CAMX, STO:ORX, TTNP By: David Franklin Click here to download report (.pdf)   Summary of Findings Weekly and monthly injectable buprenorphine treatments that could significantly affect the medication-assisted treatment (MAT) market for […]

Read more...

Buprenorphine Idea Proposal (INDV)

Buprenorphine Idea Proposal (INDV)

How will the new long-acting buprenorphine treatment option and changing government rules affect the opioid treatment market? Report Available:March 2, 2017   Blueshift’s initial research found the opioid dependence treatment market on the verge of a major disruption. Due to the opioid addiction epidemic, government rules and regulations are allowing physicians to expand the number […]

Read more...

HEDIS Will Create Modest Growth for Exact Sciences’ Cologuard (EXAS)

Research Question: Will the inclusion of Cologuard in the 2017 HEDIS quality measures drive growth for Exact Sciences? Companies: DGX, EPGNF, EXAS, GE, LH, SIEGY, TYO:6502 By: David Franklin Click here to download report (.pdf)   Summary of Findings The inclusion and equal footing of Exact Sciences Corp.’s (EXAS) Cologuard in the 2017 Healthcare Effectiveness Data […]

Read more...

Perrigo Recovery Will Happen, Expected to Take Time

Research Question: Will Perrigo recover from a recent string of negative developments to see growth over the short and long term in its three main business lines? Companies: GSK, JNJ, MYL, PRGO, TEVA By: David Franklin Click here to download the report (.pdf)   Summary of Findings Perrigo Co. plc (PRGO) is expected to recover over time […]

Read more...

Perrigo Idea Proposal

Perrigo Idea Proposal

Will Perrigo recover from a recent string of negative developments to see short and long term growth in its three main business lines? Report Available: June 10, 2016   Blueshift’s initial research shows uncertainty in the quality of PRGO’s business and their long term trajectory. The company pre-announced Q1 earnings and revenue below Street expectations […]

Read more...

Apr 08 2016 Pharmaceuticals

Market Ready to Adopt Long-Acting Buprenorphine As Opioid Treatment Option

Research Question:Will long-acting implantable and injectable buprenorphine become widely adopted for opioid addiction treatment? Companies: ALKS, BDSI, HRTX, LON:INDV, STO:CAMX, STO:ORX, TLV:TEVA, TSX:GUD, TTNP By: David Franklin Click here to download the report (.pdf)   Summary of Findings Long-acting implantable and injectable buprenorphine is expected to become an important tool and gain a significant foothold […]

Read more...

Teleflex Idea Proposal

Teleflex Idea Proposal

Will hospitals continue to accept price hikes for Teleflex’s vascular products when competitors are dropping prices? Report Available: April 20, 2016   Blueshift’s initial research shows TFX has benefited from a broad healthcare/medical device product line, a deep product pipeline, and the ability to command higher prices than the competition. With the healthcare spending growth […]

Read more...

Buprenorphine Opioid Addiction Treatment Idea Proposal

Buprenorphine Opioid Addiction Treatment Idea Proposal

Will long acting implantable and injectable buprenorphine become widely adopted for opioid addiction treatment? Report Available: April 8, 2016   Blueshift’s initial research shows that addiction to opioids has skyrocketed to the point of being an epidemic. Current available treatment options face numerous challenges including frequent dosing, poor adherence, high incidence of relapse, and misuse. […]

Read more...

Blockbuster Sales Not in Store for Depomed’s Nucynta

Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as the company takes on OxyContin among acute pain patients and Lyrica and Cymbalta in neuropathic pain patients? Companies: DEPO, HZNP, JNJ, LLY, PFE, TSE:ENL By: David Franklin Click here to download the report (.pdf)   Summary of Findings Depomed Inc.’s (DEPO) Nucynta and Nucynta […]

Read more...

Depomed Idea Proposal (DEPO)

Depomed Idea Proposal (DEPO)

Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as it takes on OxyContin with acute pain patients and Lyrica/Cymbalta with neuropathic pain patients? Report Available: Oct. 29, 2015   Blueshift’s initial research shows DEPO sold $57 million worth of painkiller Nucynta in its first quarter and believes it has the potential to reach $1 […]

Read more...